课题基金 / 基金详情

Preclinical Vector Core

Preclinical Vector Core
临床前载体核心
批准号:
7144460
负责人:
ANDREA GAMBOTTO
金额:
$71.21万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-29 至 2006-08-31

项目摘要

项目成果

ANDREA GAMBOTTO的其他基金

相似基金

相关文献

中文摘要
翻译
载体核心已经并将在国家心肺和血液研究所的框架内作为一个动态资源发挥作用,它可以提供最先进的病毒载体技术以及开发新的载体。载体核心能够产生逆转录病毒、腺病毒、腺相关病毒和疱疹病毒载体用于基因传递。载体核心将继续开发和提供逆转录病毒、腺病毒、腺相关病毒和疱疹病毒载体的库存,用于基因传递。载体核心的作用仍然是为国家心肺和血液研究所的研究人员构建和提供表达适当基因的载体。此外,该核心还将向NHLBI资助的研究人员提供所需的细胞系、病毒、包装线、质粒和方案。核心还将继续与NHLBI调查人员合作,优化病毒和非病毒基因传递和基因表达,并根据需要在使用病毒和非病毒载体进行基因转移方面提供技术援助和培训。
英文摘要
The Vector Core has been and will function within the framework of the National Heart, Lung, and Blood Institute as a dynamic resource that can provide state-of-the-art viral vector technology as well as develop novel vectors. The Vector Core is able to generate retroviral, adenoviral, adeno-associated virus and herpesvirus vectors for gene delivery. The Vector Core will continue to develop and provide stocks of retroviral, adenoviral, adeno-associated and herpesviral vectors for gene delivery. The role of the Vector Core will remain to be to construct and provide vectors expressing the appropriate genes for investigators within the National Heart, Lung, and Blood Institute. In addition, the core will provide cell lines, viruses, packaging lines, plasmids, and protocols as needed to NHLBI funded investigators. The Core also will maintain to work with the NHLBI investigators to optimize viral and non-viral gene delivery and gene expression and provide technical assistance and training in the use of viral and non-viral vectors for gene transfer as needed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
U01 Proposal Transfer - 2021
  • 批准号:
    10406767
  • 项目类别:
  • 资助金额:
    $325.08万
  • 财政年份:
    2019
  • 负责人:
    ANDREA GAMBOTTO
  • 依托单位:
Pre-clinical evaluation of a Zika virus vaccine
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine
海外基金